Guardant Health, Inc.

Services-Medical Laboratories

GHSolid5 of 9 basics passed

$167.40

+1.11%

Market cap $22.5B

$167.40

+1.11%

Market cap $22.5B

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening.

It is a $22.5B healthcare company. Revenue grew 42.7% over the last year, and it currently loses money.

Website: guardanthealth.com
Location: Palo Alto, CA
Employees: 2 506
Sector: Healthcare

Share price · 3 years

$28.73 → $167.40+482.7%

price only — dividends excluded

Key facts · TTM

Revenue: total sales; $1.18B
Loss: spends more than it earns; -$453M
Free cash flow: cash left after running the business; -$241M
Shares: up 24% since 2021 — dilution; 125.4M
Volatility: beta vs the market — under 1 swings less; 1.69

Revenue, last 8 years

52-week range

Low $61.73$167.40High $187.22

Today's price is 84% of the way from the year's low to its high.

Valuation vs own history

P/S

19.0×

10%

P/B

51.5×

Share of the last ~5 years that was pricier than today (unusually expensive vs its own history). Based on the daily valuation record.

Standing in Healthcare

Size$22.5Btop 55%
Revenue growth+30%top 11%
Net margin-38%top 87%
Return on equity-247%top 99%

Ranked against 98 Healthcare companies with a full CV — for P/E, lower ranks higher.

Skills

Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.

Valuation, Growth, Profitability, Quality and Moat lag behind.

Valuation25

P/E vs own historyn/a · 10/25
FCF yield-1.1% · 0/25
P/S19.0x · 5/25
EV/EBITDAn/a · 10/25

Growth25

Revenue CAGR27.3% · 25/25
Net income CAGRn/a · 0/25
EPS CAGR ~5Yn/a · 0/25
Fwd implied growthn/a · 0/25

Profitability0

ROICn/a · 0/25
ROE-246.6% · 0/25
Net margin-38.3% · 0/25
Operating margin-40.2% · 0/25

Health50

Altman Z4.47 · 25/25
Current ratio4.03 · 25/25
Interest coverage-151.0x · 0/25
Net cash / debtn/a · 0/25

Quality40

Piotroski F5/9 · 15/25
Beneish M-3.19 · 25/25
FCF conversionn/a · 0/25
Margin stabilityσ 32.2% · 0/25

Moat0

ROIC >12% yearsn/a · 0/25
Median gross margin-94.5% · 0/25
FCF-positive years0/8 yrs · 0/25
Worst-year net marginworst -145.6% · 0/25

How the scores work →

Experience

The company's career so far — founding, the IPO, landmark products and acquisitions, plus revenue milestones and insider buying.

2022Milestone
Guardant Health enrolled the first patient in the Screening for High-Frequency Malignant Disease (SHIELD)…
2021Product
Guardant Health introduced Guardant Reveal, the first blood-only liquid biopsy test for the detection of…
2019Product
Guardant Health launched the early-stage cancer assay called Lunar for academic and biopharmaceutical research in 2019
2018IPO
The company's U.S. initial public offering in 2018 raised $237.5 million, valuing Guardant Health at $3.3 billion
2018Acquisition
The joint venture, called Guardant Health AMEA, launched in 2018 and was purchased by Guardant Health for…
2017Product
The GuardantOMNI test launched in 2017 and has been used for biopharmaceutical research

Achievements

Verifiable track record, straight from the reported numbers.

$10 000 invested in 2021 would be worth ~$13 037 today — price return only

$982.0M revenue in FY2025

Revenue up 42.7% year over year

2 506 employees

Strengths & watch-outs

What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.

Strengths

High gross margin (65.0%)
Revenue growing 42.7% year over year
Altman Z-Score 4.47 — low bankruptcy-risk zone

Watch-outs

Not profitable — 38.3% net margin
Negative free cash flow (-$240.7M)
Thin interest coverage (-151.0×)
Loss-making in 8 of the recent years

Qualifications

The basics a company should meet before you research it further. Each check uses the reported numbers.

5 of 9 checks passed

Revenue growing — the company sells more than a year ago+42.7% YoY
Profitable — makes more than it spends-$453M TTM
Profit growing — earnings are higher than last year+4.6% YoY
Generates cash — cash left after running and investing-$241M TTM
Debt under control — could handle its obligationscurrent ratio 4.03
Established company — not a micro-cap — lower blow-up risk$22.5B market cap
Not printing shares — share count not ballooning — you keep your slice+23.7% shares over ~5y
Proven track record — years of profitability behind it0/8 profitable years
Financially stable — balance sheet not near distressAltman Z 4.5 — safe
Pays a dividend — returns cash to shareholdersno data
Valuation not extreme — price not wildly above earningsno data

Peer comparisonGuardant Health, Inc. vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾

Company	Market cap	P/E	Revenue growth	Net margin	Profile
GH this company	$22.5B	—	+42.7%	-38.3%	Solid
LLY Eli Lilly & Co.	$1.0T	41.6	+49.6%	33.5%	Solid
JNJ Johnson & Johnson	$630.9B	29.9	+8.1%	21.5%	Mixed
ABBV Abbvie Inc.	$488.5B	77.4	+10.4%	9.8%	Mixed
MRK Merck & Co., Inc.	$361.0B	113.2	+4.6%	4.8%	Mixed
UNH UNITEDHEALTH GROUP INCORPORATED (Delaware)	$340.7B	24.1	+6.5%	3.1%	Mixed
NVS Novartis AG	$273.2B	20.3	+9.6%	24.7%	Solid

Head-to-head: GH vs LLY · GH vs JNJ · GH vs ABBV

References

What covering analysts publish about the company — information only, not a recommendation.

Strong buy 15Buy 17Hold 3

Appendix · Financial records

The full statements behind this CV, FY2018–FY2025. For readers who want to check the numbers.

Profit & lossRevenue $1.18B · net income -$453M (TTM)Open ▾

Profit & loss

Revenue and profit over the company's career — the income statement, visualised.

How FY2025 revenue flows to profit

RevenueNet income

Revenue (TTM)

$1.18B

YoY 42.7%

Net income (TTM)

-$453M

Margin -38.3%

Gross margin

65.0%

Operating margin

-40.2%

Income statement — full detail

Figures in USD billions · EPS in USD

	2020	2021	2022	2023	2024	2025
Revenue	0.3	0.4	0.4	0.6	0.7	1.0
Gross profit	-0.3	-0.4	-0.5	-0.6	-0.4	0.6
Operating income (EBIT)	-0.3	-0.4	-0.5	-0.6	-0.4	-0.4
Net income	-0.3	-0.4	-0.7	-0.5	-0.4	-0.4
EPS (diluted)	—	-4.00	-6.41	-4.28	-3.56	-3.32

Cash flowFree cash flow -$241M · operating cash flow -$185M (TTM)Open ▾

Cash flow statement

Cash generated by the business and what is left after investment — year by year.

Operating cash flowFree cash flow

Free cash flow (TTM)

-$241M

Margin -20.3%

Operating cash flow (TTM)

-$185M

FCF margin

-20.3%

Cash flow statement — full detail

Figures in USD billions

	2020	2021	2022	2023	2024	2025
Operating cash flow	-0.1	-0.2	-0.3	-0.3	-0.2	-0.2
Capital expenditure	-0.0	-0.1	-0.1	-0.0	-0.0	-0.0
Free cash flow	-0.1	-0.3	-0.4	-0.3	-0.3	-0.2
FCF margin	-48.9%	-76.0%	-86.1%	-61.3%	-37.2%	-23.7%

Balance sheetAssets $2.01B · debt n/a (FY2025)Open ▾

Balance sheet

How the balance sheet is built — what it owns versus how it is financed.

How $2.01B of assets is financed

105%

Liabilities $2.11B — borrowed moneyEquity -$99.3M — owners' stake

Altman Z-Score

4.47

Safe zone

Interest coverage

-151.0x

EBIT ÷ interest expense

ROE

-246.6%

Profit per $1 of equity

Balance sheet — full detail

Figures in USD billions

	2020	2021	2022	2023	2024	2025
Cash & equivalents	1.8	0.9	1.0	1.2	0.8	1.2
Total assets	2.3	2.2	1.6	1.8	1.5	2.0
Total liabilities	0.9	1.6	1.5	1.6	1.6	2.1
Total debt	—	—	—	—	—	—
Equity	1.3	0.6	0.1	0.2	-0.1	-0.1
Net debt	—	—	—	—	—	—

Want the live picture — intraday moves, valuation history and full analysis?

Deeper analysis of GH on PreMarketPrice

Figures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $167.40 · market cap $22.5B.